Business Context and Reporting Period
Company: Oncocyte Corporation (Note: Input metadata referenced "Insight Molecular Diagnostics Inc.", but the filing text identifies the registrant as Oncocyte Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: April 13, 2022
Event: Entry into a Material Definitive Agreement for a registered direct offering of Series A Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
- Instrument: 11,765 shares of Series A Convertible Preferred Stock.
- Aggregate Gross Proceeds: $10,000,000 (to be closed in two equal tranches of $5,000,000 each).
- Purchase Price: $850 per share (including original issue discount to a stated value of $1,000 per share).
- Conversion Terms: Convertible into 7,689,542 shares of common stock at a conversion price of $1.53 per share.
- Dividend Rate: 6% per annum cumulative, payable quarterly in cash or accrued to stated value.
- Use of Proceeds: General corporate purposes and working capital.
- Liquidity Covenants: Company must maintain at least $8 million in unrestricted, unencumbered cash.
- Debt Covenants: Aggregate indebtedness limited to $15 million (excluding permitted indebtedness).
Material Changes and Structural Impacts
This filing represents a significant capital raise and a change in the company's capital structure. The issuance of Preferred Stock introduces senior equity with specific liquidation preferences and voting rights regarding amendments affecting the stock. The transaction includes a beneficial ownership limitation of 4.99% (with an election to increase to 19.99% at the first closing) to prevent excessive dilution upon conversion.
Guidance, Outlook, and Risks
- Redemption Triggers: The Preferred Stock must be redeemed for cash on the earlier of April 8, 2024, a Change of Control Transaction, bankruptcy proceedings, or if the company fails to meet the $8 million Cash Minimum Requirement (upon election by 51% of holders).
- Forced Conversion: The company may force conversion of up to one-third of the Preferred Stock if the common stock's 20-day VWAP exceeds 140% of the conversion price ($2.142) and trading volume exceeds 400,000 shares for 20 out of 30 trading days.
- Investor Participation: If the company redeems the stock and undertakes a capital raise, investors have the right to participate in the financing.
- Closing Schedule: The first closing occurs within two trading days of execution and state filing acceptance. The second closing occurs between October 8, 2022, and March 8, 2023, or earlier upon investor notice.
Key Facts for Investor Verification
- Verify the actual cash proceeds received upon the first closing (scheduled shortly after April 13, 2022).
- Monitor the company's cash balance to ensure compliance with the $8 million unrestricted cash covenant.
- Track the trading price and volume of common stock to assess the likelihood of forced conversion events.
- Confirm the filing of the Certificate of Determination with the California Secretary of State.
- Review the impact of the 6% dividend obligation on future cash flow, particularly if paid in cash rather than accrued.